NCT00647049

Freiburg ZNS-NHL Study

Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: University Hospital Freiburg · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether combined chemotherapy \[rituximab plus high dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed by high dosage carmustin/thiotepa\] followed by peripheral blood stem cell transplantation is effective in the treatment of cerebral Non Hodgkin lymphoma \[PCNSL\].

Conditions

• Primary Non Hodgkin Lymphoma of the Central Nervous System

Interventions

Type	Name	Description
DRUG	methotrexate	8000mg/m2 i.v., max. 2 cycles
DRUG	Rituximab	375mg/m2, max. 8 times
DRUG	Cytarabine	3000mg/m2 die i.v., 2 days (max. 2 cycles)
DRUG	Thiotepa	40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
DRUG	Carmustin	400mg/m2 i.v. for 1 day

Timeline

• Start date: 2007-01-01
• Primary completion: 2013-05-01
• Completion: 2013-08-01
• First posted: 2008-03-31
• Last updated: 2009-11-17

Locations

1 site across 1 country: Germany